Melanoma & Skin Cancer

RP1 plus nivolumab offers durable responses and a favorable safety profile for patients with melanoma after progression on anti–PD-1 therapy.

Pembrolizumab continued to demonstrate improved survival vs ipilimumab in unresectable stage III or IV melanoma.

The CheckMate 067 trial of patients with advanced melanoma is the longest follow-up of a checkpoint inhibitor in any tumor type.

Findings from the phase 2 RELATIVITY-104 study demonstrates a clinical benefit with the addition of relatlimab to nivolumab and chemotherapy.

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

First-line bel-sar displayed tumor control and preserved visual acuity in early-stage choroidal melanoma.

About 8 to 10 million Americans over 40 have excess white blood cells, which may increase their risk of melanoma.

The FDA has granted fast track designation to the MCR1-targeted theranostic ligand VMT01 for unresectable or metastatic melanoma.

The FDA has granted fast track designation to IBI363 for unresectable advanced or metastatic melanoma after progression on at least 1 line of therapy.

The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

Ankit Mangla, MD, expands on key survival data from the phase 2/3 RELATIVITY-047 trial in previously untreated, unresectable, or metastatic melanoma.

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.

Jeffrey S. Weber, MD, PhD, inductee of the 2016 Giants of Cancer Care award in Melanoma, has died.

Treatment with VP-315 led to reductions in tumor size in patients with basal cell carcinoma.

A sNDA seeking the approval of toripalimab for frontline use in patients with unresectable or metastatic melanoma is under review by the NMPA.

A tumor-informed ctDNA assay showed high sensitivity and specificity as well as potential for ctDNA to be used as a prognostic biomarker during surveillance in Merkel cell carcinoma.

Integrating 15-GEP with PRAME expression status into a 4-group prognostic classification system showed prognostic accuracy in uveal melanoma.

The addition of BNT111 to cemiplimab has produced clinical activity in anti-PD-(L)1 relapsed/refractory unresectable stage III or IV melanoma.

The FDA has accepted the resubmission of a BLA for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

Adjuvant nivolumab plus ipilimumab significantly improved 3-year DMFS rates compared with historical controls in patients with high-risk uveal melanoma.

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab for the treatment of cutaneous squamous cell carcinoma.

The FDA has granted fast track designation to OBX-115 for advanced melanoma that is refractory to or relapsed after immune checkpoint inhibitors.

The FDA has received a biologics license application resubmission for cosibelimab in locally advanced or metastatic cutaneous squamous cell carcinoma.

COMBI-AD (NCT01682083) evaluated dabrafenib plus trametinib for patients with BRAF-mutated AJCC-stage III melanoma, and here the final results for RFS, distant-metastasis-free survival and overall survival are presented.

PIVOTAL (NCT02938299) is an open label, randomized, multicenter, phase 3 trial evaluating Daromun as a neoadjuvant intralesional therapy for resectable, locally advanced Stage III melanoma.